1209448-44-1Relevant academic research and scientific papers
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis
Schnute, Mark E.,O'Brien, Patrick M.,Nahra, Joe,Morris, Mark,Howard Roark,Hanau, Cathleen E.,Ruminski, Peter G.,Scholten, Jeffrey A.,Fletcher, Theresa R.,Hamper, Bruce C.,Carroll, Jeffery N.,Patt, William C.,Shieh, Huey S.,Collins, Brandon,Pavlovsky, Alexander G.,Palmquist, Katherine E.,Aston, Karl W.,Hitchcock, Jeffrey,Rogers, Michael D.,McDonald, Joseph,Johnson, Adam R.,Munie, Grace E.,Wittwer, Arthur J.,Man, Chiu-Fai,Settle, Steven L.,Nemirovskiy, Olga,Vickery, Lillian E.,Agawal, Arun,Dyer, Richard D.,Sunyer, Teresa
scheme or table, p. 576 - 580 (2010/04/26)
Potent, highly selective and orally-bioavailable MMP-13 inhibitors have been identified based upon a (pyridin-4-yl)-2H-tetrazole scaffold. Co-crystal structure analysis revealed that the inhibitors bind at the S1′ active site pocket
